Midatech Pharma Plc Net debt/EBITDA
Что обозначает Net debt/EBITDA в Midatech Pharma Plc?
Net debt/EBITDA Midatech Pharma Plc является 1.88
Какое определение для Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA компаний в Health Care сектор на LSE по сравнению с Midatech Pharma Plc
Что делает Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Компании с net debt/ebitda похож на Midatech Pharma Plc
- Amaero Intl Ltd имеет Net debt/EBITDA из 1.87
- Neo Battery Materials имеет Net debt/EBITDA из 1.87
- AgEagle Aerial Systems имеет Net debt/EBITDA из 1.87
- Aridis Pharmaceuticals Inc имеет Net debt/EBITDA из 1.87
- Rio2 имеет Net debt/EBITDA из 1.87
- Artelo Biosciences Inc имеет Net debt/EBITDA из 1.87
- Midatech Pharma Plc имеет Net debt/EBITDA из 1.88
- Huaxi имеет Net debt/EBITDA из 1.88
- Kadmon Inc имеет Net debt/EBITDA из 1.88
- Ascentage Pharma Grp Intl имеет Net debt/EBITDA из 1.88
- Great-West Lifeco имеет Net debt/EBITDA из 1.88
- Nabriva Therapeutics Plc имеет Net debt/EBITDA из 1.89
- Austal имеет Net debt/EBITDA из 1.89